Lexicon Pharmaceuticals, Inc.LXRXNASDAQ
LOADING
|||
Switch Symbol:
Gross Profit Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year gross profit growth rate
Latest
-50.55%
↑ 97% above average
Average (39q)
-1870.12%
Historical baseline
Range
High:3417.31%
Low:-71769.57%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -50.55% |
| Q2 2025 | 2226.06% |
| Q1 2025 | 98.39% |
| Q4 2024 | -63.01% |
| Q3 2024 | 13.37% |
| Q2 2024 | 55.08% |
| Q1 2024 | 106.76% |
| Q4 2023 | -9216.13% |
| Q3 2023 | -49.84% |
| Q2 2023 | 1187.50% |
| Q1 2023 | 132.00% |
| Q4 2022 | -292.31% |
| Q3 2022 | 11.43% |
| Q2 2022 | 148.61% |
| Q1 2022 | 99.56% |
| Q4 2021 | -71769.57% |
| Q3 2021 | 100.23% |
| Q2 2021 | 20.34% |
| Q1 2021 | -1486.63% |
| Q4 2020 | -113.21% |
| Q3 2020 | -28.86% |
| Q2 2020 | 13.51% |
| Q1 2020 | -6.56% |
| Q4 2019 | -97.29% |
| Q3 2019 | 3417.31% |
| Q2 2019 | -3.56% |
| Q1 2019 | -47.50% |
| Q4 2018 | 161.73% |
| Q3 2018 | -51.18% |
| Q2 2018 | -47.66% |
| Q1 2018 | -24.10% |
| Q4 2017 | 23.41% |
| Q3 2017 | 128.75% |
| Q2 2017 | -36.26% |
| Q1 2017 | 204.06% |
| Q4 2016 | 30.03% |
| Q3 2016 | 11.77% |
| Q2 2016 | -14.77% |
| Q1 2016 | -125.31% |
| Q4 2015 | 529.53% |